ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approves Abbott’s HER-2 DNA Probe Kit.

January 25, 2002

NCI Cooperative Group, Cancer Center Trials Listed

September 26, 2008

Did Iressa Data Merit Approval? Experts Discuss Implications For Drug Development, Lung Cancer Treatment, Reimbursement (12-page issue).

May 9, 2003

Turnover In Immunology Contracts To Free Up Substantial Sums, Possible New RFPs Listed

October 8, 1976

Radiotherapy Plus Cetuximab May Control Head/Neck Cancer

November 26, 2010

Business & Regulatory Report March edition (8 pages) included.

March 19, 2004